"Anti-Obesity Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.
| Descriptor ID |
D019440
|
| MeSH Number(s) |
D27.505.954.427.140
|
| Concept/Terms |
Anti-Obesity Agents- Anti-Obesity Agents
- Agents, Anti-Obesity
- Anti Obesity Agents
- Anti-Obesity Drugs
- Anti Obesity Drugs
- Drugs, Anti-Obesity
- Antiobesity Drugs
- Drugs, Antiobesity
- Antiobesity Agents
- Agents, Antiobesity
Weight-Loss Agents- Weight-Loss Agents
- Agents, Weight-Loss
- Weight Loss Agents
- Weight-Loss Drugs
- Drugs, Weight-Loss
- Weight Loss Drugs
|
Below are MeSH descriptors whose meaning is more general than "Anti-Obesity Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Obesity Agents".
This graph shows the total number of publications written about "Anti-Obesity Agents" by people in this website by year, and whether "Anti-Obesity Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Obesity Agents" by people in Profiles.
-
An efficient approach to expand equitable access to antiobesity medications: deprescribing after weight loss plateau. Am J Manag Care. 2024 Aug; 30(8):348-350.
-
Medicare Part D Coverage of Antiobesity Medications - Challenges and Uncertainty Ahead. N Engl J Med. 2023 Mar 16; 388(11):961-963.
-
Pharmacotherapy of obesity in complex diseases. Clin Obes. 2022 Feb; 12(1):e12497.
-
Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation. World J Gastroenterol. 2016 Dec 07; 22(45):10071-10076.
-
Combining Pharmacological and Psychological Treatments for Binge Eating Disorder: Current Status, Limitations, and Future Directions. Curr Psychiatry Rep. 2016 Jun; 18(6):55.
-
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004.
-
Rutin Increases Muscle Mitochondrial Biogenesis with AMPK Activation in High-Fat Diet-Induced Obese Rats. Nutrients. 2015 Sep 22; 7(9):8152-69.
-
Resveratrol attenuates intermittent hypoxia-induced macrophage migration to visceral white adipose tissue and insulin resistance in male mice. Endocrinology. 2015 Feb; 156(2):437-43.
-
Effect of resveratrol on visceral white adipose tissue inflammation and insulin sensitivity in a mouse model of sleep apnea. Int J Obes (Lond). 2015 Mar; 39(3):418-23.
-
Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index =27 kg/m(2). Am J Cardiol. 2013 Apr 15; 111(8):1131-8.